Drug Database
Back to search

Poland· PL-100349194

Osaver

A olmesartan medoxomil product containing olmesartanum medoxomilum, registered in Poland by Zentiva, k.s.. The same ATC class is registered in 15 of our 19 countries.

ATC C09CA08

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedOsaverATCC09CA08REGISTER NO.PL-100349194PACKS LISTED10CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about olmesartanum medoxomilumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Olmesartan medoxomil is registered in 15 of 19 countries.

Countries holding a registration under ATC C09CA08 (olmesartan medoxomil), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 10 of them publish a price we can compare per daily dose
Search olmesartan medoxomil products by name

Olmesartan medoxomil · ATC C09CA08

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of olmesartan medoxomil costs, country by country.

Normalised to the WHO defined daily dose (20 mg), the median price runs from $0.33 in Italy to $0.86 in Switzerland — a ×2.6 gap.

  • 3 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Olmesartan medoxomil · price per daily dose (20 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$0.86
  • ES Spain$0.41
  • IT Italy$0.33
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Olmesartanum medoxomilum
Manufacturer
Zentiva, k.s.
Country
Poland (PL)
ATC code
C09CA08
ATC class
Olmesartan medoxomil
Defined daily dose
20 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 10

  • gtin
    05909991276348
  • gtin
    05909991276355
  • gtin
    05909991276362
  • gtin
    05909991276379
  • gtin
    05909991276386
  • gtin
    05909991276393
  • gtin
    05909991276409
  • gtin
    05909991276416
  • gtin
    05909991276423
  • gtin
    05909991276430

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

216 interactions on record for olmesartan medoxomil.

Graded by severity as the source publishes them — 7 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check olmesartan medoxomil against other medicinesHow interaction checks work

Olmesartan medoxomil · interactions on record

216 records

  • 7 severe
  • 128 moderate

Most severe, free to view

  • Potassium chlorideA12BA01severe
  • Potassium citrateA12BA02severe
  • Potassium gluconateA12BA05severe
  • Potassium chlorideB05XA01severe

81 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Olmesartan medoxomil in 4 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All olmesartan medoxomil products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f5b4ebe0-18a5-408a-804c-5e37688781e9
GET /v1/drugs/f5b4ebe0-18a5-408a-804c-5e37688781e9?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "40 mg",
  "packaging": "05909991276348 ¦ Rp ¦ 115866\n14 tabl.\n05909991276355 ¦ Rp ¦ 115867\n28 tabl.\n05909991276362 ¦ Rp ¦ 115868\n30 tabl.\n05909991276379 ¦ Rp ¦ 115869\n50 tabl.\n05909991276386 ¦ Rp ¦ 115870\n56 tabl.\n05909991276393 ¦ Rp ¦ 115871\n84 tabl.\n05909991276409 ¦ Rp ¦ 115872\n90 tabl.\n05909991276416 ¦ Rp ¦ 115873\n98 tabl.\n05909991276423 ¦ Rp ¦ 115874\n100 tabl.\n05909991276430 ¦ Rp ¦ 115875\n500 tabl.",
  "substance": "Olmesartanum medoxomilum 40 mg",
  "common_name": "Olmesartanum medoxomilum",
  "pl_product_id": "100349194",
  "pozwolenie_nr": "23211",
  "auth_procedure": "MRP",
  "authorisation_validity": "Bezterminowe"
}
API referenceMCP serverPlans

See everything about olmesartan medoxomil.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console